Dabur India responded to concerns regarding the quality of its honey. The company clarified that every batch of honey it produces complies with the standards set by the Food Safety and Standards Authority of India (FSSAI). Earlier news reports had claimed that Dabur’s honey contained cancer-causing materials.
Ankush Jain, the CFO of Dabur India, stated that the company stands by the purity of its honey and ensures compliance with FSSAI standards during the entire production process, from the receipt of raw materials to the final packaging. He dismissed the news report as a “motivated” one.
To further emphasize the quality of their honey, the company also mentioned that they recently received an EGGMARK special note certification. Additionally, Dabur’s honey is manufactured in facilities certified by the US Food and Drug Administration (FDA).
Dabur India reported a rise in first-quarter profit, with a 5.4% year-on-year increase in consolidated net profit to Rs 464 crore in the quarter ended June 30. The company’s revenue in the same period rose by nearly 11% to 31.30 billion rupees, driven largely by growth in its consumer care business.
It’s worth noting that the article provides Dabur’s side of the story and does not delve into the specific details of the alleged controversy or the news reports that raised concerns about the honey’s quality. For a comprehensive understanding of the issue, it would be essential to refer to the original news reports and any official statements from regulatory bodies or independent investigations.